Part 3.2 / M13, M15
3. PARTE 3: TABLA DE CLASIFICACIÓN Y ETIQUETADO ARMONIZADOS
|
N.o Índice |
►M18 Nombre químico ◄ |
N.o CE |
N.o CAS |
Clasificación |
Etiquetado |
►M18 Límites de concentración específicos, factores M y ETA (*1) ◄ |
Notas |
|||
|
Códigos de clase y categoría de peligro |
Códigos de indicaciones de peligro |
Códigos de pictogramas y palabras de advertencia |
Códigos de indicaciones de peligro |
Códigos de indicaciones de peligro suplementarias |
||||||
|
005-020-00-3 |
octaborato de disodio anhidro; [1] octaborato de disodio tetrahidratado [2] |
234-541-0 [1] 234-541-0 [2] |
12008-41-2 [1] 12280-03-4 [2] |
Repr. 1B |
H360FD |
GHS08 Dgr |
H360FD |
|
|
|
|
006-035-00-8 |
pirimicarb (ISO); 2-(dimetilamino)-5,6-dimetilpirimidin-4-il dimetilcarbamato |
245-430-1 |
Carc. 2 Acute Tox. 3 Acute Tox. 3 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H331 H301 H317 H400 H410 |
GHS08 GHS06 GHS09 Dgr |
H351 H331 H301 H317 H410 |
|
M = 10 M = 100 |
|
|
|
006-046-00-8 |
Bendiocarb (ISO); N-metilcarbamato de 2,2-dimetil-1,3-benzodioxol-4-ilo; metilcarbamato de 2,2-dimetil-1,3-benzodioxol-4-ilo |
245-216-8 |
Acute Tox. 3 Acute Tox. 3 Acute Tox. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H331 H311 H300 H400 H410 |
GHS06 GHS09 Dgr |
H331 H311 H300 H410 |
|
M = 10 M = 100 |
|
|
|
014-046-00-4 |
microfibras de vidrio E de composición representativa: [fibras de calcio-aluminio-silicio con orientación aleatoria con la siguiente composición representativa (% en peso): SiO2 50,0-56,0 %, Al2O3 13,0-16,0 %, B2O3 5,8-10,0 %, Na2O < 0,6 %, K2O < 0,4 %, CaO 15,0-24,0 %, MgO < 5,5 %, Fe2O3 < 0,5 %, F2 < 1,0 %; procesos de fabricación: producidos habitualmente por estirado a la llama y procesos de rotación (pueden estar presentes otros elementos en niveles bajos; la lista de los procesos no excluye la innovación).] |
— |
— |
Carc. 1B |
H350i |
GHS08 Dgr |
H350i |
|
|
A |
|
014-047-00-X |
microfibras de vidrio de composición representativa: [fibras de calcio-aluminio-silicio con orientación aleatoria con la siguiente composición (% en peso): SiO2 55,0-60,0 %, Al2O3 4,0-7,0 %, B2O3 8,0-11,0 %, ZrO2 0,0-4,0 %, Na2O 9,5-13,5 %, K2O 0,0-4,0 %, CaO 1,0-5,0 %, MgO 0,0-2,0 %, Fe2O3 < 0,2 %, ZnO 2,0-5,0 %, BaO 3,0-6,0 %, F2 < 1,0 %; procesos de fabricación: producidos habitualmente por estirado a la llama y procesos de rotación (pueden estar presentes otros elementos en niveles bajos; la lista de los procesos no excluye la innovación).] |
— |
— |
Carc. 2 |
H351 (inhalación) |
GHS08 Wng |
H351 (inhalación) |
|
|
A |
|
047-003-00-3 |
Zeolita de plata y cinc (zeolita, tipo marco LTA, modificada en superficie con iones de plata y cinc) [esta entrada incluye a la zeolita de tipo de marco LTA (tipo A de Linde) que se ha modificado en superficie con iones tanto de plata como de cinc, con un contenido de Ag+ del 0,5 %-6 %, de Zn2+ del 5 %-16 %, y posiblemente con fósforo, NH4 +, Mg2+ o Ca2+, cada uno a un nivel < 3 %] |
— |
Repr. 2 Skin Irrit. 2 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H361d H315 H318 H400 H410 |
GHS08 GHS05 GHS09 Dgr |
H361d H315 H318 H410 |
|
M = 100 M = 100 |
|
|
|
048-012-00-5 |
Carbonato de cadmio |
208-168-9 |
Carc. 1B Muta. 1B Acute Tox. 4* Acute Tox. 4* Acute Tox. 4* STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350 H340 H332 H312 H302 H372 (riñones, huesos) H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350 H340 H332 H312 H302 H372 (riñones, huesos) H410 |
|
|
A1 |
|
|
048-013-00-0 |
Hidróxido de cadmio; dihidróxido de cadmio |
244-168-5 |
Carc. 1B Muta. 1B Acute Tox. 4* Acute Tox. 4* Acute Tox. 4* STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350 H340 H332 H312 H302 H372 (riñones, huesos) H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350 H340 H332 H312 H302 H372 (riñones, huesos) H410 |
|
|
A1 |
|
|
048-014-00-6 |
Nitrato de cadmio; dinitrato de cadmio |
233-710-6 |
Carc. 1B Muta. 1B Acute Tox. 4* Acute Tox. 4* Acute Tox. 4* STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H350 H340 H332 H312 H302 H372 (riñones, huesos) H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H350 H340 H332 H312 H302 H372 (riñones, huesos) H410 |
|
Carc. 1B; H350: C ≥ 0,01 % |
A1 |
|
|
050-030-00-3 |
Dilaurato de dibutilestaño; dibutil-[bis(dodecanoiloxi)]-estannano |
201-039-8 |
Muta. 2 Repr. 1B STOT RE 1 |
H341 H360FD H372 (sistema inmunitario) |
GHS08 Dgr |
H341 H360FD H372 (sistema inmunitario) |
|
|
|
|
|
602-020-00-0 |
1,2-dicloropropano; dicloruro de propileno |
201-152-2 |
Flam. Liq. 2 Carc. 1B Acute Tox. 4* Acute Tox. 4* |
H225 H350 H332 H302 |
GHS02 GHS08 GHS07 Dgr |
H225 H350 H332 H302 |
|
|
|
|
|
602-033-00-1 |
clorobenceno |
203-628-5 |
Flam. Liq. 3 Acute Tox. 4 Skin Irrit. 2 Aquatic Chronic 2 |
H226 H332 H315 H411 |
GHS02 GHS07 GHS09 Wng |
H226 H332 H315 H411 |
|
|
|
|
|
603-055-00-4 |
óxido de propileno; 1,2-epoxipropano; metiloxirano |
200-879-2 |
Flam. Liq. 1 Carc. 1B Muta. 1B Acute Tox. 3 Acute Tox. 3 Acute Tox. 4 STOT SE 3 Eye Irrit. 2 |
H 224 H350 H340 H331 H311 H302 H335 H319 |
GHS02 GHS08 GHS06 Dgr |
H224 H350 H340 H331 H311 H302 H335 H319 |
|
|
|
|
|
603-235-00-2 |
Linalol; 3,7-dimetil-1,6-octadien-3-ol; dl-linalol; [1] coriandrol; (S)-3,7-dimetil-1,6-octadien-3-ol; d-linalol; [2] licareol; (R)-3,7-dimetil-1,6-octadien-3-ol; l-linalol [3] |
201-134-4 [1] 204-810-7 [2] 204-811-2 [3] |
78-70-6 [1] 126-90-9 [2] 126-91-0 [3] |
Skin Sens. 1B |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
604-057-00-8 |
Masa de reacción de: isómeros de 2-(2H-benzotriazol-2-il)-4-metil-(n)-dodecilfenol; isómeros de 2-(2H-benzotriazol-2-il)-4-metil-(n)-tetracosilfenol; isómeros de 2-(2H-benzotriazol-2-il)-4-metil-5,6-didodecilfenol n = 5 o 6 |
401-680-5 |
— |
Aquatic Chronic 4 |
H413 |
|
H413 |
|
|
|
|
604-092-00-9 |
fenol, dodecil-, ramificado; [1] fenol, 2-dodecil-, ramificado; [2] fenol, 3-dodecil-, ramificado; [3] fenol, 4-dodecil-, ramificado; [4] fenol, derivados tetrapropenílicos [5] |
310-154-3 [1] [2] [3] [4] [5] |
121158-58-5 [1] [2] [3] 210555-94-5 [4] 74499-35-7 [5] |
Repr. 1B Skin Corr. 1C Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H360F H314 H318 H400 H410 |
GHS08 GHS05 GHS09 Dgr |
H360F H314 H410 |
|
M = 10 M = 10 |
|
|
604-093-00-4 |
Clorofeno; 2-bencil-4-clorofenol |
204-385-8 |
Carc. 2 Repr. 2 Acute Tox. 4 Skin Irrit. 2 Skin Sens. 1 Eye Dam. 1 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H361f H332 H315 H317 H318 H373 (riñones) H400 H410 |
GHS08 GHS05 GHS07 GHS09 Dgr |
H351 H361f H332 H315 H317 H318 H373 (riñones) H410 |
|
M = 1 M = 100 |
|
|
|
605-013-00-0 |
cloralosa (DCI); (R)-1,2-O-(2,2,2-tricloroetiliden)-α-D-glucofuranosa; glucocloralosa; anhidroglucocloral |
240-016-7 |
Acute Tox. 4* Acute Tox. 3 STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 |
H332 H301 H336 H400 H410 |
GHS06 GHS09 Dgr |
H332 H301 H336 H410 |
|
M = 10 M = 10 |
C |
|
|
605-022-00-X |
glutaral; glutaraldehído; 1,5-pentanodial |
203-856-5 |
Acute Tox. 2 Acute Tox. 3 STOT SE 3 Skin Corr. 1B Resp. Sens. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 2 |
H330 H301 H335 H314 H334 H317 H400 H411 |
GHS06 GHS05 GHS08 GHS09 Dgr |
H330 H301 H335 H314 H334 H317 H410 |
EUH071 |
STOT SE 3; H335: 0,5 % ≤ C < 5 % M = 1 |
|
|
|
605-023-00-5 |
5-Cloro-2-(4-clorofenoxi)fenol; [DCPP] |
429-290-0 |
Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H318 H400 H410 |
GHS05 GHS09 Dgr |
H318 H410 |
|
M = 10 M = 10 |
|
|
|
605-040-00-8 |
hidroxiisohexil 3-ciclohexeno carboxaldehído (INCI); masa de reacción de 4-(4-hidroxi-4-metilpentil)ciclohex-3-eno-1-carbaldehído y 3-(4-hidroxi-4-metilpentil)ciclohex-3-eno-1-carbaldehído; [1] 4-(4-hidroxi-4-metilpentil)ciclohex-3-eno-1-carbaldehído; [2] 3-(4-hidroxi-4-metilpentil)ciclohex-3-eno-1-carbaldehído [3] |
- [1] 250-863-4 [2] 257-187-9 [3] |
130066-44-3 [1] 31906-04-4 [2] 51414-25-6 [3] |
Skin Sens. 1A |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
606-014-00-9 |
clorofacinona (ISO); 2-[(4-clorofenil)(fenil)acetil]-1H-indeno-1,3(2H)-diona |
223-003-0 |
Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H360D H330 H310 H300 H372 (sangre) H400 H410 |
GHS08 GHS06 GHS09 Dgr |
H360D H330 H310 H300 H372 (sangre) H410 |
|
Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (sangre): C ≥ 0,1 % STOT RE 2; H373 (sangre): 0,01 % ≤ C < 0,1 % M = 1 M = 1 |
|
|
|
606-021-00-7 |
N-metil-2-pirrolidona; 1-metil-2-pirrolidona |
212-828-1 |
Repr. 1B STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 |
H360D*** H335 H315 H319 |
GHS08 GHS07 Dgr |
H360D*** H335 H315 H319 |
|
STOT SE 3; H335: C ≥ 10 % |
|
|
|
606-041-00-6 |
2-Metil-1-(4-(metiltiofenil)-2-morfolinopropan-1-ona |
400-600-6 |
Repr. 1B Acute Tox. 4* Aquatic Chronic 2 |
H360FD H302 H411 |
GHS08 GHS07 GHS09 Dgr |
H360FD H302 H411 |
|
|
|
|
|
606-150-00-9 |
Cletodim (ISO); (5RS)-2-{(1EZ)-1- [(2E)-3-cloroaliloxiimino]propil}-5-[(2RS)-2-(etiltio)propil]-3-hidroxiciclohex-2-en-1-ona |
— |
Acute Tox. 4 Skin Sens. 1 Aquatic Chronic 3 |
H302 H317 H412 |
GHS07 Wng |
H302 H317 H412 |
EUH066 |
|
|
|
|
606-151-00-4 |
Antraquinona |
201-549-0 |
Carc. 1B |
H350 |
GHS08 Dgr |
H350 |
|
|
|
|
|
607-056-00-0 |
warfarina (ISO); 4-hidroxi-3-(3-oxo-1-fenilbutil)-2H-cromen-2-ona; [1] (S)-4-hidroxi-3-(3-oxo-1-fenilbutil)-2-benzopirona; [2] (R)-4-hidroxi-3-(3-oxo-1-fenilbutil)-2-benzopirona [3] |
201-377-6 [1] 226-907-3 [2] 226-908-9 [3] |
81-81-2 [1] [2] [3] |
Repr. 1A Acute Tox. 1 Acute Tox. 1 Acute Tox. 2 STOT RE 1 Aquatic Chronic 2 |
H360D H330 H310 H300 H372 (sangre) H411 |
GHS08 GHS06 GHS09 Dgr |
H360D H330 H310 H300 H372 (sangre) H411 |
|
Repr. 1A; H360D: C ≥ 0,003 % STOT RE 1; H372 (sangre): C ≥ 0,5 % STOT RE 2; H373 (sangre): 0,05 % ≤ C < 0,5 % |
|
|
607-059-00-7 |
cumatetralilo (ISO); 4-hidroxi-3-(1,2,3,4-tetrahidro-1-naftil)cumarina |
227-424-0 |
Repr. 1B Acute Tox. 2 Acute Tox. 3 Acute Tox. 2 STOT RE 1 Aquatic Chronic 1 |
H360D H330 H311 H300 H372 (sangre) H410 |
GHS08 GHS06 GHS09 Dgr |
H360D H330 H311 H300 H372 (sangre) H410 |
|
Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (sangre): C ≥ 1,0 % STOT RE 2; H373 (sangre) 0,1 % ≤ C < 1,0 % M = 10 |
|
|
|
607-123-00-4 |
Metacrilato de 2,3-epoxipropilo; metacrilato de glicidilo |
203-441-9 |
Carc. 1B Muta. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 STOT SE 3 STOT RE 1 Eye Dam. 1 Skin Corr. 1C Skin Sens. 1 |
H350 H341 H360F H311 H302 H335 H372 (vías respiratorias) (inhalación) H318 H314 H317 |
GHS08 GHS06 GHS05 Dgr |
H350 H341 H360F H311 H302 H335 H372 (vías respiratorias) (inhalación) H314 H317 |
|
|
D |
|
|
607-157-00-X |
difenácum (ISO); 3-(3-bifenil-4-il-1,2,3,4-tetrahidro-1-naftil)-4-hidroxicumarina |
259-978-4 |
Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H360D H330 H310 H300 H372 (sangre) H400 H410 |
GHS08 GHS06 GHS09 Dgr |
H360D H330 H310 H300 H372 (sangre) H410 |
|
Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (sangre): C ≥ 0,02 % STOT RE 2; H373 (sangre): 0,002 % ≤ C < 0,02 % M = 10 M = 10 |
|
|
|
607-172-00-1 |
brodifácum (ISO); 4-hidroxi-3-(3-(4′-bromo-4-bifenilil)-1,2,3,4-tetrahidro-1-naftil)cumarina |
259-980-5 |
Repr. 1A Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H360D H330 H310 H300 H372 (sangre) H400 H410 |
GHS08 GHS06 GHS09 Dgr |
H360D H330 H310 H300 H372 (sangre) H410 |
|
Repr. 1A; H360D: C ≥ 0,003 % STOT RE 1; H372 (sangre): C ≥ 0,02 % STOT RE 2; H373 (sangre): 0,002 % ≤ C < 0,02 % M = 10 M = 10 |
|
|
|
607-375-00-5 |
flocumafén (ISO); masa de reacción de: cis-4-hidroxi-3-(1,2,3,4-tetrahidro-3-(4-(4-trifluorometilbenciloxi)fenil)-1-naftil)cumarina y trans-4-hidroxi-3-(1,2,3,4-tetrahidro-3-(4-(4-trifluorometilbenciloxi)fenil)-1-naftil)cumarina |
421-960-0 |
Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H360D H330 H310 H300 H372 (sangre) H400 H410 |
GHS08 GHS06 GHS09 Dgr |
H360D H330 H310 H300 H372 (sangre) H410 |
|
Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (sangre): C ≥ 0,05 % STOT RE 2; H373 (sangre): 0,005 % ≤ C < 0,05 % M = 10 M = 10 |
|
|
|
607-623-00-2 |
ftalato de diisobutilo |
201-553-2 |
Repr. 1B |
H360Df |
GHS08 Dgr |
H360Df |
|
|
|
|
|
607-716-00-8 |
bromadiolona (ISO); 3-[3-(4′-bromobifenil-4-il)-3-hidroxi-1-fenilpropil]-4-hidroxi-2H-cromen-2-ona |
249-205-9 |
Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H360D H330 H310 H300 H372 (sangre) H400 H410 |
GHS08 GHS06 GHS09 Dgr |
H360D H330 H310 H300 H372 (sangre) H410 |
|
Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (sangre): C ≥ 0,005 % STOT RE 2; H373 (sangre): 0,0005 % ≤ C < 0,005 % M = 1 M = 1 |
|
|
|
607-717-00-3 |
difetialona (ISO); 3-[3-(4′-bromobifenil-4-il)-1,2,3,4-tetrahidronaftalen-1-il]-4-hidroxi-2H-1-benzotiopiran-2-ona |
— |
Repr. 1B Acute Tox. 1 Acute Tox. 1 Acute Tox. 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H360D H330 H310 H300 H372 (sangre) H400 H410 |
GHS08 GHS06 GHS09 Dgr |
H360D H330 H310 H300 H372 (sangre) H410 |
EUH070 |
Repr. 1B; H360D: C ≥ 0,003 % STOT RE 1; H372 (sangre): C ≥ 0,02 % STOT RE 2; H373 (sangre): 0,002 % ≤ C < 0,02 % M = 100 M = 100 |
|
|
|
607-718-00-9 |
ácido perfluorononan-1-oico [1] y sus sales de sodio [2] y amonio [3] |
206-801-3 [1] [2] [3] |
375-95-1 [1] 21049-39-8 [2] 4149-60-4 [3] |
Carc. 2 Repr. 1B Lact. Acute Tox. 4 Acute Tox. 4 STOT RE 1 Eye Dam. 1 |
H351 H360Df H362 H332 H302 H372 (hígado, timo, bazo) H318 |
GSH08 GSH07 GHS05 Dgr |
H351 H360Df H362 H332 H302 H372 (hígado, timo, bazo) H318 |
|
|
|
|
607-719-00-4 |
ftalato de diciclohexilo |
201-545-9 |
Repr. 1B Skin Sens. 1 |
H360D H317 |
GHS08 GHS07 Dgr |
H360D H317 |
|
|
|
|
|
607-720-00-X |
Ácido nonadecafluorodecanoico; [1] nonadecafluorodecanoato de amonio; [2] nonadecafluorodecanoato de sodio [3] |
206-400-3 [1] 221-470-5 [2] [3] |
3830-45-3 [3] |
Carc. 2 Repr. 1B Lact. |
H351 H360Df H362 |
GHS08 Dgr |
H351 H360Df H362 |
|
|
|
|
607-721-00-5 |
N,N′-Metilen-dimorfolina; N,N′-metilen-bismorfolina; [formaldehído liberado de N,N′-metilen-bismorfolina]; [MBM] |
227-062-3 |
Carc. 1B Muta. 2 Acute Tox. 4 Acute Tox. 4 Acute Tox. 4 STOT RE 2 Skin Corr. 1B Skin Sens. 1 Eye Dam. 1 |
H350 H341 H332 H312 H302 H373 (aparato digestivo, vías respiratorias) H314 H317 H318 |
GHS08 GHS07 GHS05 Dgr |
H350 H341 H332 H312 H302 H373 (aparato digestivo, vías respiratorias) H314 H317 |
EUH071 |
|
8 9 |
|
|
607-722-00-0 |
(Z)-(1R,3R)-3-(2-Cianoprop-1-enil)-2,2-dimetilciclopropanocarboxilato de 2,3,5,6-tetrafluoro-4-(metoximetil)bencilo; épsilon-momfluorotrina |
— |
Acute Tox. 4 STOT SE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H371 (sistema nervioso) H400 H410 |
GHS07 GHS08 GHS09 Wng |
H302 H371 (sistema nervioso) H410 |
|
M = 100 M = 100 |
|
|
|
607-723-00-6 |
Teflutrina (ISO); (1RS, 3RS)-3-[(Z)-2-cloro-3,3,3-trifluoroprop-1-enil]-2,2-dimetilciclopropano-carboxilato de 2,3,5,6-tetrafluoro-4-metilbencilo |
— |
Acute Tox. 1 Acute Tox. 2 Acute Tox. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H330 H310 H300 H400 H410 |
GHS06 GHS09 Dgr |
H330 H310 H300 H410 |
|
M = 10 000 M = 10 000 |
|
|
|
608-055-00-8 |
Fipronil (ISO); (±)-5-amino-1-(2,6-dicloro--α,α,α-trifluoro-para-tolil)-4-trifluorometilsulfinil-pirazol-3-carbonitrilo |
424-610-5 |
Acute Tox. 3* Acute Tox. 3* Acute Tox. 3* STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H301 H311 H331 H372* H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H301 H311 H331 H372* H410 |
|
M = 1 000 M = 10 000 |
|
|
|
608-067-00-3 |
3,7-dimetilocta-2,6-dienonitrilo |
225-918-0 |
Muta. 1B |
H340 |
GHS08 Dgr |
H340 |
|
|
|
|
|
612-150-00-X |
Espiroxamina (ISO); 8-terc-butil-1,4-dioxaespiro[4.5] decan-2-ilmetil(etil)(propil)amina |
— |
Repr. 2 Acute Tox. 4 Acute Tox. 4 Acute Tox. 4 STOT RE 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H361d H332 H312 H302 H373 (ojos) H315 H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H361d H332 H312 H302 H373 (ojos) H315 H317 H410 |
|
M = 100 M = 100 |
|
|
|
612-288-00-0 |
bupirimato (ISO); 5-butil-2-etilamino-6-metilpirimidin-4-il dimetilsulfamato |
255-391-2 |
Carc. 2 Skin Sens. 1B Aquatic Chronic 1 |
H351 H317 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H317 H410 |
|
M = 1 |
|
|
|
612-289-00-6 |
triflumizol (ISO); (1E)-N-[4-cloro-2-(trifluorometil)fenil]-1-(1H-imidazol-1-il)-2-propoxietanimina |
— |
Repr. 1B Acute Tox. 4 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H360D H302 H373 (hígado) H317 H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H360D H302 H373 (hígado) H317 H410 |
|
M = 1 M = 1 |
|
|
|
612-290-00-1 |
Productos de reacción de paraformaldehído con 2-hidroxipropilamina (proporción 3:2); [formaldehído liberado de 3,3′-metilen-bis[5-metiloxazolidina]; formaldehído liberado de oxazolidina]; [MBO] |
— |
— |
Carc. 1B Muta. 2 Acute Tox. 4 Acute Tox. 3 Acute Tox. 4 STOT RE 2 Skin Corr. 1B Eye Dam. 1 Skin Sens. 1 A Aquatic Chronic 2 |
H350 H341 H332 H311 H302 H373 (aparato digestivo, vías respiratorias) H314 H318 H317 H411 |
GHS08 GHS06 GHS05 GHS09 Dgr |
H350 H341 H332 H311 H302 H373 (aparato digestivo, vías respiratorias) H314 H317 H411 |
EUH071 |
|
8 9 |
|
612-291-00-7 |
Productos de reacción de paraformaldehído con 2-hidroxipropilamina (proporción 1:1); [formaldehído liberado de α, α,α-trimetil-1,3,5-triazina-1,3,5(2H, 4H, 6H)-trietanol]; [HPT] |
— |
— |
Carc. 1B Muta. 2 Acute Tox. 4 Acute Tox. 4 STOT RE 2 Skin Corr. 1C Eye Dam. 1 Skin Sens. 1 A Aquatic Chronic 2 |
H350 H341 H332 H302 H373 (aparato digestivo, vías respiratorias) H314 H318 H317 H411 |
GHS08 GHS07 GHS05 GHS09 Dgr |
H350 H341 H332 H302 H373 (aparato digestivo, vías respiratorias) H314 H317 H411 |
EUH071 |
|
8 9 |
|
612-292-00-2 |
Metilhidrazina |
200-471-4 |
Carc. 1B |
H350 |
GHS08 Dgr |
H350 |
|
|
|
|
|
613-121-00-4 |
clorosulfurón (ISO); 2-cloro-N-[[(4-metoxi-6-metil-1,3,5-triazin-2-il)amino]carbonil]bencenosulfonamida |
265-268-5 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
M = 1 000 M = 100 |
|
|
|
613-318-00-5 |
Fenpirazamina (ISO); 5-amino-2,3-dihidro-2-isopropil-3-oxo-4-(o-tolil)pirazol-1-carbotioato de S-alilo 5-amino-2-isopropil-4-(2-metilfenil)-3-oxo-2,3-dihidropirazol-1-carbotioato de S-alilo |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
M = 10 M = 1 |
|
|
|
613-321-00-1 |
(RS)-4-[1-(2,3-dimetilfenil)etil]-1H-imidazol; medetomidina |
— |
Acute Tox. 2 Acute Tox. 2 STOT SE 3 STOT SE 1 STOT RE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H330 H300 H336 H370 (ojos) H372 H400 H410 |
GHS06 GHS08 GHS09 Dgr |
H330 H300 H336 H370 (ojos) H372 H410 |
|
M = 1 M = 100 |
|
|
|
613-322-00-7 |
Triadimenol (ISO); (1RS,2RS;1RS,2SR)-1-(4-clorofenoxi)-3,3-dimetil-1-(1H-1,2,4-triazol-1-il)butan-2-ol; α-terc-butil-β-(4-clorofenoxi)-1H-1,2,4-triazol-1-etanol |
259-537-6 |
Repr. 1B Lact. Acute Tox. 4 Aquatic Chronic 2 |
H360 H362 H302 H411 |
GHS08 GHS07 GHS09 Dgr |
H360 H362 H302 H411 |
|
|
|
|
|
613-323-00-2 |
Terbutilazina (ISO); N-terc-butil-6-cloro-N′-etil-1,3,5-triazina-2,4-diamina |
227-637-9 |
Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H373 H400 H410 |
GHS07 GHS08 GHS09 Wng |
H302 H373 H410 |
|
M = 10 M = 10 |
|
|
|
613-324-00-8 |
Quinolin-8-ol; 8-hidroxiquinoleína |
205-711-1 |
Repr. 1B Acute Tox. 3 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H360D H301 H318 H317 H400 H410 |
GHS08 GHS06 GHS05 GHS09 Dgr |
H360D H301 H318 H317 H410 |
|
M = 1 M = 1 |
|
|
|
613-325-00-3 |
Tiacloprid (ISO); (Z)-3-(6-cloro-3-piridilmetil)-1,3-tiazolidin-2-iliden-cianamida; {(2Z)-3-[(6-cloropiridin-3-il)metil]-1,3-tiazolidin-2-iliden} cianamida |
— |
Carc. 2 Repr. 1B Acute Tox. 4 Acute Tox. 3 STOT SE 3 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H360FD H332 H301 H336 H400 H410 |
GHS08 GHS06 GHS09 Dgr |
H351 H360FD H332 H301 H336 H410 |
|
M = 100 M = 100 |
|
|
|
615-013-00-2 |
Cianamida; carbamonitrilo |
206-992-3 |
Carc. 2 Repr. 2 Acute Tox. 3 Acute Tox. 3 STOT RE 2 Skin Corr. 1 Skin Sens. 1 Eye Dam. 1 Aquatic Chronic 3 |
H351 H361fd H311 H301 H373 (tiroides) H314 H317 H318 H412 |
GHS08 GHS06 GHS05 Dgr |
H351 H361fd H311 H301 H373 (tiroides) H314 H317 H412 |
|
|
|
|
|
616-006-00-7 |
Diclofluanida (ISO); N-[(diclorofluorometil)tio]-N′,N′-dimetil-N-fenilsulfamida |
214-118-7 |
Acute Tox. 4 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 |
H332 H319 H317 H400 |
GHS07 GHS09 Wng |
H332 H319 H317 H400 |
|
M = 10 |
|
|
|
616-011-00-4 |
N,N-dimetilacetamida |
204-826-4 |
Repr. 1B Acute Tox. 4* Acute Tox. 4* |
H360D*** H332 H312 |
GHS08 GHS07 Dgr |
H360D*** H332 H312 |
|
|
|
|
|
616-037-00-6 |
acetocloro (ISO); 2-cloro-N-(etoximetil)-N-(2-etil- 6-metilfenil)acetamida |
251-899-3 |
Carc. 2 Repr. 2 Acute Tox. 4 STOT SE 3 STOT RE 2 Skin Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H361f H332 H335 H373 (riñón) H315 H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H361f H332 H335 H373 (riñón) H315 H317 H410 |
|
M = 1 000 M = 100 |
|
|
|
616-094-00-7 |
3,3′-Diciclohexil-1,1′-metilen-bis(4,1-fenilen)diurea |
406-370-3 |
Aquatic Chronic 4 |
H413 |
|
H413 |
|
|
|
|
|
616-207-00-X |
clorhidrato de polihexametilen-biguanida; PHMB |
— |
Carc. 2 Acute Tox. 2 Acute Tox. 4 STOT RE 1 Eye Dam. 1 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 |
H351 H330 H302 H372 (vías respiratorias) (inhalación) H318 H317 H400 H410 |
GHS08 GHS06 GHS05 GHS09 Dgr |
H351 H330 H302 H372 (vías respiratorias) (inhalación) H318 H317 H410 |
|
M = 10 M = 10 |
|
|
|
616-218-00-X |
benzovindiflupir (ISO); N-[9-(diclorometileno)-1,2,3,4-tetrahidro-1,4-metanonaftalen-5-il]-3-(difluorometil)-1-metil-1H-pirazol-4-carboxamida |
— |
Acute Tox. 3 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 |
H331 H301 H400 H410 |
GHS06 GHS09 Dgr |
H331 H301 H410 |
|
M = 100 M = 100 |
|
|
|
616-219-00-5 |
fluopiram (ISO); N-{2-[3-cloro-5-(trifluorometil)piridin-2-il]etil}-2-(trifluorometil)benzamida |
— |
Aquatic Chronic 2 |
H411 |
GHS09 |
H411 |
|
|
|
|
|
616-220-00-0 |
pencicurón (ISO); 1-[(4-clorofenil)metil]-1-ciclopentil-3-fenilurea |
266-096-3 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
M = 1 M = 1 |
|
|
|
616-221-00-6 |
Hexaflumurón (ISO); 1-(3,5-dicloro-4-(1,1,2,2-tetrafluoroetoxi)fenil)-3-(2,6-difluorobenzoil)urea |
401-400-1 |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
M = 1 000 M = 10 000 |
|
|
|
616-222-00-1 |
Pentiopirad (ISO); (RS)-N-[2-(1,3-dimetilbutil)-3-tienil]-1-metil-3-(trifluorometil)pirazol-4-carboxamida |
— |
Aquatic Acute 1 Aquatic Chronic 1 |
H400 H410 |
GHS09 Wng |
H410 |
|
M = 1 M = 1 |
|
|
|
616-223-00-7 |
Carbetamida (ISO); carbanilato de (R)-1-(etilcarbamoil)etilo; fenilcarbamato de (2R)-1-(etilamino)-1-oxopropan-2-ilo |
240-286-6 |
Carc. 2 Repr. 1B Acute Tox. 4 Aquatic Chronic 2 |
H351 H360D H302 H411 |
GHS08 GHS07 GHS09 Dgr |
H351 H360D H302 H411 |
|
|
|
|
|
617-023-00-2 |
hidroperóxido de terc-butilo |
200-915-7 |
Muta. 2 |
H341 |
GHS08 Wng |
H341 |
|
|
|
|
|
650-032-00-X |
Ciproconazol (ISO); (2RS,3RS;2RS,3SR)-2-(4-clorofenil)-3-ciclopropil-1-(1H-1,2,4-triazol-1-il)butan-2-ol |
— |
Repr. 1B Acute Tox. 3 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H360D H301 H373 (hígado) H400 H410 |
GHS08 GHS06 GHS09 Dgr |
H360D H301 H373 (hígado) H410 |
|
M = 10 M = 1 |
|
|